Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome Size and the Evolution of New Genes03:21

Genome Size and the Evolution of New Genes

7.5K
While every living organism has a genome of some kind (be it RNA, or DNA), there is considerable variation in the sizes of these blueprints. One major factor that impacts genome size is whether the organism is prokaryotic or eukaryotic. In prokaryotes, the genome contains little to no non-coding sequence, such that genes are tightly clustered in groups or operons sequentially along the chromosome. Conversely, the genes in eukaryotes are punctuated by long stretches of non-coding sequence.
7.5K
Second Uniqueness Theorem01:16

Second Uniqueness Theorem

1.4K
Consider a region consisting of several individual conductors with a definite charge density in the region between these conductors. The second uniqueness theorem states that if the total charge on each conductor and the charge density in the in-between region are known, then the electric field can be uniquely determined.
In contrast, consider that the electric field is non-unique and apply Gauss's law in divergence form in the region between the conductors and the integral form to the surface...
1.4K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

257
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
257
Unusual Results01:16

Unusual Results

3.0K
Unusual results are those that have a very low chance of occurring. Unusual results can be identified using probabilities and the range rule of thumb. In problems involving probability, unusual results can be observed in 2 instances – an unusually high number of successes or an unusually low number of successes.
According to the range rule of thumb, any value above or below two standard deviations, 2σ  from the mean, μ  is considered unusual.
Maximum unusual value =...
3.0K
Other Unique Bacteria01:18

Other Unique Bacteria

576
Magnetic bacteria exhibit a directed movement called magnetotaxis, driven by structures called magnetosomes. These magnetosomes consist of chains of magnetic particles made of either magnetite (Fe₃O₄) or greigite (Fe₃S₄) and are organized in a linear conformation by a protein scaffold within invaginations of the cell membrane. The bacteria align along the north–south magnetic field lines, much like a compass needle. They are typically microaerophilic or anaerobic...
576
Null and Alternative Hypotheses01:16

Null and Alternative Hypotheses

9.1K
The actual hypothesis testing begins by considering two hypotheses. They are termed  the null hypothesis and the alternative hypothesis. These hypotheses contain opposing viewpoints.
The null hypothesis, denoted by H0 is a statement of no difference between the variables—they are not related. This can often be considered the status quo. As  a result if you cannot accept the null, it requires some action.
The alternative hypothesis, denoted by H1 or Ha, is a claim about the...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monitoring and feedback using data in transfusion medicine: A study of practices from the BEST Collaborative.

Transfusion·2026
Same author

TRACTION for Greater Surgical Use of Tranexamic Acid.

The New England journal of medicine·2026
Same author

Electronic patient blood management monitoring using routine health record data: A proof-of-principle study monitoring perioperative tranexamic acid use.

Transfusion·2026
Same author

Staff satisfaction with the use of bedside electronic transfusion checks at three hospitals in London.

Vox sanguinis·2026
Same author

Transforming transfusion safety: Insights from implementing bedside electronic checks at a large UK National Health Service trust.

Vox sanguinis·2026
Same author

Transforming transfusion practice in the National Health Service to enhance safety, efficiency and clinical outcomes.

British journal of haematology·2026
Same journal

Utilization, Spending, and Price of Opioid Medications in the US Medicaid Programs Between 1991 and 2019.

American health & drug benefits·2022
Same journal

A Hollywood-Style Teachable Moment.

American health & drug benefits·2022
Same journal

Migration of Hospital Total Hip and Knee Arthroplasty Procedures to an Ambulatory Surgery Center Setting and Postsurgical Opioid Use: A Private Practice Experience.

American health & drug benefits·2022
Same journal

Multiple Sclerosis: Systemic Challenges to Cost-Effective Care.

American health & drug benefits·2022
Same journal

The Oncology Pipeline Overview: Recent Approvals and Near-Term Drugs.

American health & drug benefits·2022
Same journal

Mental Illness Disclosure in the Workplace: An Opportunity for Improvement.

American health & drug benefits·2022
See all related articles

Related Experiment Video

Updated: Apr 25, 2026

Novel Object Recognition and Object Location Behavioral Testing in Mice on a Budget
05:57

Novel Object Recognition and Object Location Behavioral Testing in Mice on a Budget

Published on: November 20, 2018

59.9K

When novelty is not enough.

Michael F Murphy1

  • 1Chief Medical and Scientific Officer, Worldwide Clinical Trials, Inc., Chadds Ford, PA.

American Health & Drug Benefits
|August 16, 2014
PubMed
Summary
This summary is machine-generated.

Navigating complex healthcare systems requires understanding how perceived value and evidence of clinical utility influence new pharmaceutical product introductions. Reimbursement policies significantly impact research and development, affecting healthcare innovation from discovery to patient access.

More Related Videos

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups
14:14

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups

Published on: May 13, 2022

5.8K
Novel Apparatus and Method for Drug Reinforcement
07:32

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

21.4K

Related Experiment Videos

Last Updated: Apr 25, 2026

Novel Object Recognition and Object Location Behavioral Testing in Mice on a Budget
05:57

Novel Object Recognition and Object Location Behavioral Testing in Mice on a Budget

Published on: November 20, 2018

59.9K
The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups
14:14

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups

Published on: May 13, 2022

5.8K
Novel Apparatus and Method for Drug Reinforcement
07:32

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

21.4K

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Health Services Research

Background:

  • The healthcare landscape is a complex system involving diverse stakeholders, including providers, payers, regulators, and consumers.
  • Informed decision-making for novel pharmaceutical interventions is challenging due to varying information needs across audiences, therapeutic areas, and development stages.

Purpose of the Study:

  • To analyze the multifaceted factors influencing the introduction and research of new pharmaceutical products within the current healthcare environment.
  • To examine the impact of reimbursement strategies and evidence requirements on pharmaceutical innovation and market access.

Main Methods:

  • Qualitative analysis of healthcare system structure and stakeholder interactions.
  • Review of regulatory and reimbursement policies affecting pharmaceutical development.
  • Assessment of the role of perceived value and clinical utility in product adoption.

Main Results:

  • Product viability is significantly affected by perceived value and mechanistic novelty, not just scientific merit.
  • Reimbursement policies, such as incentive-based formularies and prior authorization, profoundly influence R&D activities.
  • Evidence requirements, including those from Centers for Medicare & Medicaid Services (CMS) Coverage with Evidence Development (CED), are critical for market access.

Conclusions:

  • The economic impact and patient outcomes are key variables influencing research scope from bench to market.
  • Strategic navigation of healthcare system complexities, including payer and regulatory landscapes, is crucial for successful pharmaceutical innovation.
  • Understanding the interplay between value perception, evidence generation, and reimbursement is essential for advancing novel therapies.